UDP-N-acetyl-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase- 6 (pp-GalNAc-T6): Role in Cancer and Prospects as a Drug Target.

abstract：:Obesity is rapidly becoming a global phenomenon. This is more than a cosmetic issue as obesity is associated with several life-threatening diseases, including colon cancer. Insulin resistance and inflammation, underlying factors in obesity-related diseases, promote colonocyte proliferation and suppress programmed cell...

journal_title：Current cancer drug targets

authors： Vanamala J,Tarver CC,Murano PS

更新日期：2008-11-01 00:00:00

abstract：:Angiogenesis is a key factor in the carcinogenesis process. In oncological practice, angiogenesis inhibition, mainly through the blockade of the VEGF family and its receptors, has been robustly demonstrated to produce clinical benefits and, in specific disease subsets such as colorectal cancer, to extend the overall s...

journal_title：Current cancer drug targets

authors： Bagnasco L,Piras D,Parodi S,Bauer I,Zoppoli G,Patrone F,Ballestrero A

更新日期：2012-05-01 00:00:00

abstract：:Heat shock proteins (HSPs) are molecular chaperones that stabilize folding and conformation of normal as well as oncogenic proteins. These chaperones thereby prevent the formation of protein aggregates. HSPs are often overexpressed in human malignancies, including AML. HSP90 is the main chaperon required for the stabi...

journal_title：Current cancer drug targets

authors： Reikvam H,Ersvaer E,Bruserud O

更新日期：2009-09-01 00:00:00

abstract：:Constitutive activation of the EGFR/RAS/PI3K cell-signaling pathway that may occur through molecular aberrations in core pathway components occurs in many solid tumours, including colorectal cancer(CRC), non-small-cell lung cancer(NSCLC) and breast cancer. Predictive biomarkers of response to therapeutics targeting th...

journal_title：Current cancer drug targets

authors： Barton S,Starling N,Swanton C

更新日期：2010-12-01 00:00:00

abstract：:Lipophilic derivatives of the anticancer drug paclitaxel (PTX) were prepared by means of its conjugation to lipoamino acid (LAA) residues, with the aim of increasing drug accumulation in tumor cells. PTX was linked to the methyl esters of norleucine (C6) or 2-aminodecanoic acid (C10). A succinic acid group was used as...

journal_title：Current cancer drug targets

authors： Pignatello R,Paolino D,Pantò V,Pistară V,Calvagno MG,Russo D,Puglisi G,Fresta M

更新日期：2009-03-01 00:00:00

abstract：:Drugs that target the vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF) pathways have revolutionized the treatment of patients with metastatic renal cell cancer (RCC). Patients with clear cell RCC often have mutations or silencing of the von Hippel Lindau gene leading to an accumulati...

journal_title：Current cancer drug targets

authors： Heng DY,Bukowski RM

更新日期：2008-12-01 00:00:00

abstract：:(5Z,9Z)-11-Phenylundeca-5,9-dienoic acid was stereoselectively synthesized, based on original cross-cyclomagnesiation of 2-(hepta-5,6-dien-1-yloxy)tetrahydro-2H-pyran and buta-2,3-dien-1-ylbenzene with EtMgBr in the presence of the Cp2TiCl2 catalyst giving 2,5-dialkylydenemagnesacyclopentane in 86% yield. The acid hyd...

journal_title：Current cancer drug targets

authors： D'yakonov VA,Dzhemileva LU,Makarov AA,Mulyukova AR,Baevd DS,Khusnutdinova EK,Tolstikova TG,Dzhemilev UM

更新日期：2015-01-01 00:00:00

abstract：:The peptidyl prolyl isomerase (Pin1) that induces cis-trans isomerization of the peptide bond involving serine/threonine-proline has recently been shown to regulate the activity of many phosphoproteins including the ones involved in damage response pathways. We investigated Pin1 as a potential target for enhancing the...

journal_title：Current cancer drug targets

authors： Mathur R,Chandna S,N Kapoor P,S Dwarakanath B

更新日期：2011-03-01 00:00:00

abstract：:Therapeutic vaccines continue to be one of the most active fields in cancer research. However, despite clear evidence of antitumor effect in laboratory animals, and despite the ability of current vaccine candidates to elicit tumor specific antibodies and T-cells in humans, objective responses in the clinical trials ar...

journal_title：Current cancer drug targets

authors： Gonzalez G,Crombet T,Lage A

更新日期：2011-01-01 00:00:00

abstract：:Scaffold-based analogs of cinnamic acid benzyl amide (CABA) exhibit pleiotropic effects in cancer cells, and their exact molecular mechanism of action is under investigation. The present study is part of our systemic analysis of interactions of CABA analogs with their molecular targets. These compounds were shown to i...

journal_title：Current cancer drug targets

authors： Mielecki M,Milner-Krawczyk M,Grzelak K,Mielecki D,Krzysko KA,Lesyng B,Priebe W

更新日期：2014-01-01 00:00:00

abstract：BACKGROUND:Current gene therapy vectors such as viral, non-viral, and bacterial vectors, which are used for cancer treatment, but there are certain safety concerns and stability issues of these conventional vectors. Exosomes are the vesicles of size 40-100 nm secreted from multivesicular bodies into the extracellular e...

journal_title：Current cancer drug targets

authors： Pofali P,Mondal A,Londhe V

更新日期：2020-01-01 00:00:00

abstract：:AKT is a central signaling molecule in regulating cell survival, proliferation, tumor growth and angiogenesis. Upstream components of AKT signaling pathway such as PI3K, PTEN, and Ras are commonly mutated in many human cancers. Recently it is found that AKT plays an important role in regulating normal vascularization ...

journal_title：Current cancer drug targets

authors： Jiang BH,Liu LZ

更新日期：2008-02-01 00:00:00

abstract：:Despite advances in multidisciplinary approaches, the prognosis for most patients with malignant gliomas is poor. Malignant gliomas are highly vascularized tumors with elevated expression of vascular endothelial growth factor (VEGF), an important mediator of angiogenesis. Recent studies of bevacizumab, an anti-VEGF mo...

journal_title：Current cancer drug targets

authors： Soffietti R,Trevisan E,Bertero L,Bosa C,Ruda R

更新日期：2012-03-01 00:00:00

abstract：:Histone deacetylase inhibitors (HDACi) belong to a novel class of drugs able to act on the epigenome, indirectly remodeling the spatial conformation of the chromatin: by increasing histone acetylation these drugs ultimately promote the detachment of the DNA from the nucleosome octamer, therefore allowing the access of...

journal_title：Current cancer drug targets

authors： Rodriguez-Menendez V,Tremolizzo L,Cavaletti G

更新日期：2008-06-01 00:00:00

abstract：:Selection of treatment options for clinically localized prostate cancer is based on a host of factors including the patient's age, overall health status, potential complications, clinical tumor stage and Gleason score. It is widely acknowledged that androgen independent disease remains the main obstacle to improving t...

journal_title：Current cancer drug targets

authors： Garrison JB,Kyprianou N

更新日期：2004-02-01 00:00:00

abstract：:The capacity to induce new blood vessel formation or to repair damaged vessels is an attractive idea that has, for a long time, captured the attention and imagination of researchers. Beside the identification of the pro-angiogenic growth factors and their counterpart inhibitors, the discovery of endothelial progenitor...

journal_title：Current cancer drug targets

authors： Pasquier E,Dias S

更新日期：2010-12-01 00:00:00

abstract：:MicroRNAs (miRNAs) control the expression of approximately 60% of protein-coding genes and regulate cell metabolism, proliferation, differentiation, and apoptosis. Notably, aberrant expression of miRNAs contributes to several diseases including cancer. Accumulating evidence indicates that miRNAs play important roles i...

journal_title：Current cancer drug targets

authors： Zheng N,Yang P,Wang Z,Zhou Q

更新日期：2017-01-01 00:00:00

abstract：:Cisplatin is one of the most commonly used drugs in the treatment of gastric cancer. However, drug resistance is a major obstacle for effective treatment and originates in multiple mechanisms such as enhanced DNA repair and anti-apoptosis. Our previous results demonstrated that XRCC1 was a key regulator of cisplatin i...

journal_title：Current cancer drug targets

authors： Ni P,Xu W,Zhang Y,Chen Q,Li A,Wang S,Xu S,Zhou J

更新日期：2015-01-01 00:00:00

abstract：:Although the imatinib based therapy of chronic myeloid leukemia (CML) represents a triumph of medicine, not all patients with CML benefit from this drug due to the development of resistance and intolerance. The interruption of imatinib treatment is often followed by clinical relapse, suggesting a failure in the killin...

journal_title：Current cancer drug targets

authors： Adamia S,Pilarski PM,Bar-Natan M,Stone RM,Griffin JD

更新日期：2013-09-01 00:00:00

abstract：:The Jun oncoprotein is a major component of the transcription factor complex AP-1, which regulates the expression of multiple genes essential for cell proliferation, differentiation and apoptosis. Constitutive activation of endogenous AP-1 is required for tumor formation in avian and mammalian cell transformation syst...

journal_title：Current cancer drug targets

authors： Hartl M,Bader AG,Bister K

更新日期：2003-02-01 00:00:00

abstract：:Anchorage-independent growth, anoikis resistance, and most steps of metastasis formation are integrin-mediated or -dependent processes, which are characteristics of malignant tumor cells. Acting as oncogenes or tumor suppressor genes, integrins may be involved in the oncogenic transformation of normal cells and their ...

journal_title：Current cancer drug targets

authors： Eble JA,Haier J

更新日期：2006-03-01 00:00:00

abstract：:Recent publications on the molecular characterization of malignant glioma have had profound impact on the appreciation of tumoral heterogeneity within and between patients. Both these phenomena are implicated in the variability in clinical outcome between patients, as well as the inevitable recurrence of these tumors ...

journal_title：Current cancer drug targets

authors： Balvers RK,Dirven CM,Leenstra S,Lamfers ML

更新日期：2017-01-01 00:00:00

abstract：:The urokinase plasminogen activator (uPA) system (uPAS) consists of the uPA, its cognate receptor (uPAR) and two specific inhibitors, the plasminogen activator inhibitor 1 (PAI-1) and 2 (PAI-2). The uPA converts the proenzyme plasminogen in the serine protease plasmin, involved in a number of physiopathological proces...

journal_title：Current cancer drug targets

authors： Ulisse S,Baldini E,Sorrenti S,D'Armiento M

更新日期：2009-02-01 00:00:00

abstract：BACKGROUND:MicroRNA (miRNA) therapy, which was widely considered to treat a series of cancer, has been confronted with numerous obstacles to being delivered into target cells because of its easy biodegradation and instability. METHODS:In this research, we successfully constructed 11-mercaptoundecanoic acid modified go...

journal_title：Current cancer drug targets

authors： Yan LJ,Guo XH,Wang WP,Hu YR,Duan SF,Liu Y,Sun Z,Huang SN,Li HL

更新日期：2019-01-01 00:00:00

abstract：:Malignant gliomas are frequently chemoresistant and this resistance seems to depend on at least two mechanisms. First, the poor penetration of many anticancer drugs across the blood-brain barrier (BBB), the blood-cerebrospinal fluid barrier (BCSFB) and blood-tumor barrier (BTB), due to their interaction with several A...

journal_title：Current cancer drug targets

authors： Declèves X,Amiel A,Delattre JY,Scherrmann JM

更新日期：2006-08-01 00:00:00

abstract：:Platinum-based chemotherapeutics are the mainstay of treatment of a range of tumors achieving high response rates but limited in the course of disease by appearance of drug resistance. Tumor cells respond with reduced uptake and increased intracellular inactivation of the drugs, as well as increased DNA repair and gen...

journal_title：Current cancer drug targets

authors： Hamilton G

更新日期：2014-01-01 00:00:00

abstract：:Prostate cancer is the most frequently diagnosed tumor in industrialized countries. Endocrine therapy, which is based on interference with androgen signaling is only palliative. Drugs used in prostate cancer therapy are luteinizing hormone releasing hormone (LHRH) agonists and antiandrogens. Application of LHRH agonis...

journal_title：Current cancer drug targets

authors： Culig Z,Bartsch G,Hobisch A

更新日期：2004-08-01 00:00:00

abstract：:Membranous Met is classically identified with its role in cancer metastases, while nuclear Met is associated with a more invasive, aggressive and proliferative form of cancer. Full-length Met or N-terminal transmembrane domain cleaved Met can translocate into nucleus in a cell growth and pH dependent but both ligand-d...

journal_title：Current cancer drug targets

authors： Xie Y,Istayeva S,Chen Z,Tokay T,Zhumadilov Z,Wu D,Hortelano G,Zhang J

更新日期：2016-01-01 00:00:00

abstract：:Amplification of the HER-2 gene occurs in approximately 25% of breast cancers, causing up-regulation of key signaling pathways which control cell growth and survival. In breast cancer patients, HER-2 overexpression correlates with an aggressive phenotype and poor prognosis. HER-2, therefore, has become the focus of ma...

journal_title：Current cancer drug targets

authors： Browne BC,O'Brien N,Duffy MJ,Crown J,O'Donovan N

更新日期：2009-05-01 00:00:00

abstract：:The experimental cytotoxic drug cyclopentenyl cytosine (CPEC) is an analogue of cytidine. Besides its antiviral effect, its potential use in the treatment of cancer has become an important area of research. CPEC is activated by intracellular phosphorylation ultimately forming its metabolite CPEC-TP. CPEC-TP is a non c...

journal_title：Current cancer drug targets

authors： Schimmel KJ,Gelderblom H,Guchelaar HJ

更新日期：2007-08-01 00:00:00